MS and Demyelinating Disorders

The annual meeting will now take place October 25–28, 2021 at the Rosen Shingle Creek in Orlando, Florida.

Treatment with low-dose protocol of rituximab is sufficient to maintain suppression of inflammatory disease activity in most patients with relapsing-remitting multiple sclerosis.

The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending January 30, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.

Researchers sought to redefine dichotomous classifications of MS and identified meaningful classifications.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 22, 2021.

Source-based morphometry, a novel independent component analysis technique, was found to be useful in characterizing patterns of atrophy development.

Here's what is coming soon to NeurologyLive.

Patients with an early age of onset (AO) were also more likely to receive less effective first-line oral therapy than those with later AOs.

The FDA previously declined to approve de novo classification in April 2019.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 15, 2021.